Decreases/NNS
in/IN
Casz1/NN
mRNA/NN
by/IN
an/DT
siRNA/JJ
Complex/NN
Do/NN
not/RB
Alter/RB
Blood/NN
Pressure/NN
in/IN
Mice/NNS
./.
====================
Recent/JJ
genomewide/NN
association/NN
studies/NNS
of/IN
large/JJ
samples/NNS
have/VBP
identified/VBN
genes/NNS
that/WDT
are/VBP
associated/VBN
with/IN
blood/NN
pressure/NN
./.
====================
The/DT
Global/JJ
Blood/NN
Pressure/NN
Genetics/NNS
(/(
Global/JJ
BPgen/NN
)/)
and/CC
Cohorts/NNS
for/IN
Heart/NN
and/CC
Aging/NN
Research/NN
in/IN
Genome/NN
Epidemiology/JJ
(/(
CHARGE/NN
)/)
consortiums/VBZ
identified/VBD
14/CD
loci/NNS
that/IN
govern/VBP
blood/NN
pressure/NN
on/IN
a/DT
genomewide/JJ
significance/NN
level/NN
,/,
one/CD
of/IN
which/WDT
is/VBZ
CASZ1/NN
confirmed/VBD
in/IN
both/DT
Europeans/NNS
and/CC
Asians/NNS
./.
====================
CASZ1/NN
is/VBZ
a/DT
zinc/NN
finger/NN
transcription/NN
factor/NN
that/WDT
controls/VBZ
apoptosis/NN
and/CC
cell/NN
fate/NN
and/CC
suppresses/VBZ
neuroblastoma/NN
tumor/NN
growth/NN
by/IN
reprogramming/VBG
gene/NN
expression/NN
,/,
like/IN
a/DT
tumor/NN
suppressor/NN
./.
====================
To/TO
validate/VB
the/DT
function/NN
of/IN
CASZ1/NN
in/IN
blood/NN
pressure/NN
,/,
we/PRP
decreased/VBD
Casz1/NN
mRNA/NN
levels/NNS
in/IN
mice/NNS
by/IN
siRNA/JJ
./.
====================
Casz1/NN
siRNA/NN
reduced/VBD
mRNA/NN
levels/NNS
by/IN
59/CD
%/NN
in/IN
a/DT
mouse/NN
cell/NN
line/NN
./.
====================
A/DT
polyethylenimine-mixed/JJ
siRNA/JJ
complex/NN
was/VBD
injected/VBN
into/IN
mouse/NN
tail/NN
veins/NNS
,/,
reducing/VBG
Casz1/NN
mRNA/NN
expression/NN
to/TO
45/CD
%/NN
in/IN
the/DT
kidney/NN
./.
====================
However/RB
,/,
blood/NN
pressure/NN
in/IN
the/DT
treated/VBN
mice/NNS
was/VBD
unaffected/JJ
,/,
despite/IN
a/DT
55/CD
%/NN
reduction/NN
in/IN
Casz1/NN
mRNA/NN
levels/NNS
in/IN
the/DT
kidney/NN
on/IN
multiple/JJ
siRNA/JJ
injections/NNS
daily/RB
./.
====================
Even/RB
though/IN
Casz1/NN
siRNA-treated/JJ
mice/NNS
did/VBD
not/RB
experience/VB
any/DT
significant/JJ
change/NN
in/IN
blood/NN
pressure/NN
,/,
our/PRP$
study/NN
demonstrates/VBZ
the/DT
value/NN
of/IN
in/FW
vivo/FW
siRNA/NN
injection/NN
in/IN
analyzing/VBG
the/DT
function/NN
of/IN
candidate/NN
genes/NNS
identified/VBN
by/IN
genomewide/NN
association/NN
studies/NNS
./.
====================
CASZ1/NN
gene/NN
is/VBZ
a/DT
zinc/NN
finger/NN
transcription/NN
factor/NN
that/WDT
controls/VBZ
cell/NN
fate/NN
,/,
although/IN
little/JJ
is/VBZ
known/VBN
about/IN
its/PRP$
function/NN
[/(
1/CD
]/)
./.
====================
CASZ1/NN
is/VBZ
also/RB
known/VBN
as/IN
a/DT
survival-related/JJ
gene/NN
that/WDT
has/VBZ
2/CD
isoforms/NNS
./.
====================
It/PRP
encodes/VBZ
a/DT
putative/JJ
protein/NN
of/IN
172/CD
amino/NN
acids/NNS
that/DT
localizes/VBZ
predominantly/RB
in/IN
the/DT
perinuclear/JJ
region/NN
,/,
as/IN
predicted/VBN
for/IN
transcription/NN
factors/NNS
./.
====================
CASZ1/NN
is/VBZ
highly/RB
expressed/VBN
in/IN
many/JJ
human/JJ
cancer/NN
cell/NN
lines/NNS
,/,
although/IN
its/PRP$
expression/NN
is/VBZ
low/JJ
in/IN
most/JJS
tissues/NNS
,/,
implicating/VBG
it/PRP
in/IN
tumor/NN
growth/NN
[/(
2/CD
]/)
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
CASZ1/NN
is/VBZ
important/JJ
for/IN
cell/NN
proliferation/NN
,/,
development/NN
,/,
and/CC
differentiation/NN
,/,
as/IN
well/RB
as/IN
carcinogenesis/NN
./.
====================
However/RB
,/,
CASZ1/NN
has/VBZ
recently/RB
been/VBN
reported/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
blood/NN
pressure/NN
and/CC
hypertension/NN
in/IN
genomewide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
[/(
3/CD
]/)
./.
====================
Blood/NN
pressure/NN
GWASs/NNS
by/IN
the/DT
Global/JJ
Blood/NN
Pressure/JJ
Genetics/NNS
(/(
Global/JJ
BPgen/NN
)/)
[/(
4/CD
]/)
and/CC
the/DT
Cohorts/NNS
for/IN
Heart/RB
and/CC
Aging/NN
Research/NNP
in/IN
Genome/NNP
Epidemiology/JJ
(/(
CHARGE/NN
)/)
consortium/NN
[/(
5/CD
]/)
have/VBP
identified/VBN
14/CD
independent/JJ
loci/NNS
that/IN
govern/VBP
blood/NN
pressure/NN
or/CC
hypertension/NN
at/IN
a/DT
genomewide/JJ
significance/NN
level/NN
,/,
7/CD
of/IN
which/WDT
were/VBD
replicated/VBN
in/IN
the/DT
Japanese/JJ
population/NN
(/(
CASZ1/NNP
,/,
MTHFR/NN
,/,
ITGA9/NN
,/,
FGF5/NN
,/,
CYP17A1-CNNM2/NN
,/,
ATP2B1/NN
,/,
and/CC
CSK-ULK3/NN
)/)
[/(
6/CD
]/)
./.
====================
Single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
rs880315/NN
,/,
which/WDT
lies/VBZ
in/IN
an/DT
intron/NN
of/IN
CASZ1/NN
,/,
was/VBD
one/CD
of/IN
the/DT
7/CD
replicate/VBP
loci/NNS
(/(
p/NN
=/JJ
2.2/CD
×/CD
10-8/CD
,/,
p/NN
=/JJ
4.9/CD
×/CD
10-12/CD
,/,
and/CC
p/NN
=/JJ
3.0/CD
×/CD
10-7/CD
for/IN
systolic/JJ
blood/NN
pressure/NN
,/,
diastolic/JJ
blood/NN
pressure/NN
,/,
and/CC
hypertension/NN
,/,
respectively/RB
)/)
./.
====================
CASZ1/NN
was/VBD
also/RB
linked/VBN
to/TO
blood/NN
pressure/NN
in/IN
the/DT
Women/NN
's/POS
Genome/NN
Health/NN
Study/NN
(/(
rs880315/NN
;/:
p/NN
=/JJ
5.2/CD
×/CD
10-9/CD
for/IN
systolic/JJ
blood/NN
pressure/NN
)/)
[/(
7/CD
]/)
./.
====================
Recently/RB
,/,
the/DT
CASZ1/NN
locus/NN
was/VBD
identified/VBN
in/IN
19,608/CD
subjects/NNS
of/IN
east/JJ
Asian/JJ
ancestry/NN
by/IN
the/DT
Asian/JJ
Genetic/JJ
Epidemiology/NN
Network/NN
Blood/NN
Pressure/NN
(/(
AGEN-BP/NN
)/)
consortium/NN
[/(
8/CD
]/)
./.
====================
Although/IN
these/DT
blood/NN
pressure/NN
GWASs/NNS
have/VBP
suggested/VBN
that/IN
these/DT
loci/NNS
control/NN
blood/NN
pressure/NN
,/,
their/PRP$
function/NN
in/IN
blood/NN
pressure/NN
has/VBZ
not/RB
been/VBN
examined/VBN
./.
====================
Traditionally/RB
,/,
knockout/JJ
or/CC
transgenic/JJ
mice/NNS
have/VBP
been/VBN
used/VBN
to/TO
reveal/VB
gene/NN
function/NN
and/CC
can/MD
be/VB
good/JJ
approaches/NNS
for/IN
examining/VBG
candidate/NN
genes/NNS
that/WDT
lie/VBP
near/JJ
the/DT
GWAS/NN
loci/NNS
[/(
9/CD
]/)
./.
====================
However/RB
,/,
this/DT
process/NN
is/VBZ
expensive/JJ
and/CC
time-consuming/JJ
[/(
10/CD
]/)
,/,
requiring/VBG
technical/JJ
advances/NNS
to/TO
determine/VB
their/PRP$
function/NN
in/IN
vivo/FW
./.
====================
Small/JJ
interfering/VBG
RNA/NN
(/(
siRNA/JJ
)/)
is/VBZ
an/DT
alternative/JJ
approach/NN
that/DT
has/VBZ
the/DT
potential/JJ
to/TO
become/VB
the/DT
preferred/JJ
tool/NN
for/IN
that/DT
purpose/NN
[/(
11/CD
]/)
./.
====================
In/IN
vivo/FW
injection/NN
of/IN
siRNA/JJ
reduces/VBZ
gene/NN
expression/NN
by/IN
70/CD
%/NN
to/TO
80/CD
%/NN
in/IN
certain/JJ
tissues/NNS
in/IN
mice/NNS
,/,
demonstrating/VBG
its/PRP$
efficacy/NN
[/(
12/CD
]/)
./.
====================
However/RB
,/,
specific/JJ
tissues/NNS
can/MD
not/RB
be/VB
targeted/VBN
by/IN
in/FW
vivo/FW
injection/NN
of/IN
siRNA/JJ
,/,
and/CC
the/DT
injected/JJ
siRNA/JJ
is/VBZ
unstable/JJ
in/IN
blood/NN
serum/NN
,/,
limiting/VBG
their/PRP$
use/NN
in/IN
delivering/VBG
siRNA/JJ
in/IN
vivo/FW
./.
====================
It/PRP
also/RB
has/VBZ
certain/JJ
disadvantages/NNS
,/,
such/JJ
as/IN
effecting/VBG
inflammatory/JJ
responses/NNS
and/CC
toxicity/NN
[/(
13/CD
]/)
./.
====================
Thus/RB
,/,
developing/VBG
siRNA/JJ
delivery/NN
methods/NNS
in/IN
animal/NN
models/NNS
is/VBZ
a/DT
challenging/JJ
but/CC
worthy/NN
effort/NN
to/TO
accelerate/VB
the/DT
discovery/NN
of/IN
novel/JJ
genes/NNS
[/(
11/CD
]/)
./.
====================
We/PRP
sought/VBD
to/TO
determine/VB
whether/IN
murine/JJ
Casz1/NN
controls/NNS
blood/NN
pressure/NN
by/IN
administering/VBG
Casz1/NN
siRNA/NN
to/TO
mice/NNS
./.
====================
A/DT
polyethylenimine-mixed/JJ
siRNA/JJ
complex/NN
was/VBD
injected/VBN
into/IN
tail/NN
veins/NNS
,/,
and/CC
changes/NNS
in/IN
Casz1/NN
mRNA/NN
and/CC
blood/NN
pressure/NN
were/VBD
measured/VBN
./.
====================
Animals/NNS
====================
BALB/c/NN
mice/NNS
(/(
Japan/NNP
SLC/NN
,/,
Inc./NNP
,/,
Shizuoka/NN
,/,
Japan/NNP
)/)
were/VBD
bred/VBN
in/IN
a/DT
pathogen-free/JJ
facility/NN
and/CC
used/VBN
at/IN
7/CD
to/TO
9/CD
weeks/NNS
of/IN
age/NN
for/IN
siRNA/JJ
injection/NN
./.
====================
The/DT
mice/NNS
were/VBD
maintained/VBN
on/IN
a/DT
12-h/JJ
light/dark/NN
cycle/NN
at/IN
a/DT
constant/JJ
temperature/NN
with/IN
free/JJ
access/VBP
to/TO
food/NN
and/CC
water/NN
./.
====================
Every/RB
effort/NN
was/VBD
made/VBN
to/TO
minimize/VB
the/DT
number/NN
of/IN
animals/NNS
that/DT
was/VBD
used/VBN
and/CC
their/PRP$
suffering/VBG
per/IN
the/DT
Committee/JJ
for/IN
the/DT
Care/NN
and/CC
Use/NN
of/IN
Laboratory/JJ
Animals/NNS
,/,
College/NN
of/IN
Pharmacy/NN
,/,
Kyung/JJ
Hee/JJ
University/NN
(/(
KHP-2010-04-06/NN
)/)
./.
====================
Synthesis/NN
of/IN
siRNA/JJ
====================
Casz1/NN
siRNA/NN
oligonucleotides/NNS
were/VBD
synthesized/VBN
by/IN
Genolution/NN
(/(
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
The/DT
target/NN
sequence/NN
for/IN
Casz1/NN
was/VBD
5'-GATGTGATCCGACATTACA-3/NN
'/``
(/(
siRNA/JJ
#/CD
1/CD
)/)
,/,
5'-CTAGAACTGCTCTGTATGT-3/NN
'/``
(/(
siRNA/JJ
#/CD
2/CD
)/)
,/,
and/CC
5'-CAATTCGGCAAGTAATGGA-3/NN
'/``
(/(
siRNA/JJ
#/CD
3/CD
)/)
,/,
and/CC
nonspecific/JJ
scrambled/VBN
siRNA/JJ
was/VBD
used/VBN
as/IN
a/DT
negative/JJ
control/NN
./.
====================
To/TO
examine/VB
the/DT
efficacy/NN
of/IN
siRNAs/NNS
,/,
siRNAs/NNS
were/VBD
transfected/VBN
into/IN
B16F10/NN
cells/NNS
using/VBG
G-Fectin/NN
(/(
Genolution/NN
)/)
;/:
1-2/CD
µL/NN
of/IN
G-Fectin/NN
and/CC
20/CD
nM/NN
siRNA/JJ
were/VBD
added/VBN
to/TO
50/CD
µL/NNS
phosphate/NN
buffered/JJ
saline/NN
,/,
and/CC
the/DT
reaction/NN
was/VBD
incubated/VBN
for/IN
10/CD
min/NN
at/IN
room/JJ
temperature/NN
(/(
RT/NN
)/)
./.
====================
B16F10/NN
cells/NNS
were/VBD
used/VBN
to/TO
seed/VB
24-well/JJ
plates/VBZ
at/IN
5/CD
×/NN
104/CD
cells/well/JJ
and/CC
30/CD
%/NN
confluence/NN
,/,
and/CC
the/DT
transfection/NN
mixture/NN
was/VBD
added/VBN
to/TO
the/DT
plate/NN
./.
====================
The/DT
cells/NNS
were/VBD
harvested/VBN
for/IN
RNA/NN
extraction/NN
after/IN
24/CD
h/NN
of/IN
incubation/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
prepared/VBN
using/VBG
TRIzol/NN
(/(
Invitrogen/NN
,/,
Carlsbad/NN
,/,
CA/NN
,/,
USA/NN
)/)
per/IN
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
Delivery/RB
methods/NNS
====================
The/DT
transfection/NN
agent/NN
was/VBD
in/IN
vivo-jetPEI™/FW
(/(
Polyplus/NN
,/,
Illkirch-Graffenstaden/JJ
,/,
France/NN
)/)
./.
====================
Per/NN
the/DT
manufacturer/NN
,/,
25/CD
µg/NN
siRNA/JJ
and/CC
6.5/CD
µL/NN
vivo-jetPEI™/FW
(/(
N/P/NN
charge/NN
ratio/NN
of/IN
6/CD
)/)
were/VBD
diluted/VBN
with/IN
50/CD
µL/NN
10/CD
%/NN
glucose/NN
solution/NN
and/CC
50/CD
µL/NN
sterile/JJ
H2O/NN
./.
====================
The/DT
solution/NN
was/VBD
vortexed/VBN
gently/RB
and/CC
left/NN
for/IN
15/CD
min/NN
at/IN
RT/NN
./.
====================
The/DT
mixture/NN
was/VBD
injected/VBN
into/IN
the/DT
tail/NN
veins/NNS
of/IN
7-/CD
to/TO
9-week-old/JJ
mice/NNS
,/,
and/CC
the/DT
treated/VBN
mice/NNS
were/VBD
measured/VBN
for/IN
blood/NN
pressure/NN
or/CC
sacrificed/VBN
for/IN
RNA/NN
extraction/NN
./.
====================
RNA/NN
extraction/NN
and/CC
real-time/VBP
PCR/NN
====================
RNA/NN
was/VBD
extracted/VBN
from/IN
the/DT
tissues/NNS
of/IN
siRNA-treated/JJ
mice/NNS
with/IN
TRIzol/NN
(/(
Invitrogen/NN
)/)
./.
====================
We/PRP
synthesized/VBD
cDNA/NN
from/IN
500/CD
ng/NN
of/IN
total/JJ
RNA/NN
using/VBG
the/DT
PrimeScript™/NN
RT/NN
reagent/JJ
kit/NN
(/(
TaKaRa/NN
,/,
Otsu/NNP
,/,
Japan/NNP
)/)
per/IN
the/DT
manufacturer/NN
's/POS
protocol/NN
./.
====================
Casz1/NN
mRNA/NN
was/VBD
analyzed/VBN
by/IN
real-time/NN
PCR/NN
./.
====================
One-tenth/DT
of/IN
the/DT
cDNA/NN
reaction/NN
was/VBD
added/VBN
to/TO
a/DT
final/JJ
volume/NN
of/IN
20/CD
µL/NN
for/IN
each/DT
reaction/NN
containing/VBG
SYBR/NN
Green/NN
I/NN
(/(
TaKaRa/NN
)/)
./.
====================
The/DT
primers/NNS
for/IN
Casz1/NN
and/CC
glyceraldehye-3-phosphate/NN
dehydrogenase/NN
(/(
GAPDH/NN
)/)
were/VBD
5'-GTCTCTTCGGGAACTGCAAG-3'/5'-TGGGACACAGGCACTGTAGA-3/NN
'/``
and/CC
5'-GCTCTCTGCTCCTCCTGTTC-3'/5'-CAATACGACCAAATCCGTTG-3/NN
'/``
,/,
respectively/RB
(/(
forward/reverse/JJ
sequence/NN
)/)
./.
====================
Quantitative/JJ
real-time/RB
PCR/NN
was/VBD
performed/VBN
on/IN
an/DT
ABI/NN
Step/JJ
One/CD
Real-time/NN
PCR/NN
system/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
using/VBG
the/DT
following/VBG
program/NN
:/:
45/CD
cycles/NNS
of/IN
95℃/CD
for/IN
10/CD
s/NNS
,/,
60℃/RB
for/IN
15/CD
s/NNS
,/,
and/CC
72℃/CD
for/IN
20/CD
s./CC
To/TO
normalize/VB
the/DT
amount/NN
of/IN
sample/JJ
cDNA/NN
in/IN
each/DT
reaction/NN
,/,
the/DT
Ct/JJ
value/NN
of/IN
each/DT
target/NN
gene/NN
was/VBD
subtracted/VBN
by/IN
that/DT
of/IN
GAPDH/JJ
to/TO
obtain/DT
delta/NN
Ct/NNP
[/(
14/CD
]/)
./.
====================
To/TO
calculate/VB
the/DT
fold-change/NN
in/IN
expression/NN
,/,
the/DT
delta/NN
Ct/NN
value/NN
of/IN
the/DT
case/NN
sample/NN
was/VBD
subtracted/VBN
by/IN
that/DT
of/IN
the/DT
control/NN
(/(
delta/NN
delta/NN
Ct/NN
=/JJ
delta/NN
Ct/NN
case/NN
-/:
delta/NN
Ct/NN
control/NN
)/)
./.
====================
Reverse-transcription/NN
PCR/NN
was/VBD
performed/VBN
similarly/RB
to/TO
quantitative/JJ
real-time/NN
PCR/NN
,/,
except/IN
that/DT
it/PRP
used/VBN
35/CD
cycles/NNS
for/IN
amplification/NN
./.
====================
The/DT
PCR/NN
products/NNS
were/VBD
separated/VBN
by/IN
electrophoresis/NN
in/IN
a/DT
2.0/CD
%/NN
agarose/IN
gel/NN
and/CC
visualized/VBD
under/IN
UV/NN
lamp/NN
after/IN
ethidium/NN
bromide/NN
staining/NN
./.
====================
Blood/NN
pressure/NN
measurement/NN
====================
Blood/NN
pressure/NN
was/VBD
recorded/VBN
intraarterially/RB
with/IN
a/DT
computerized/VBN
data/NNS
acquisition/NN
system/NN
(/(
ADInstruments/NNS
,/,
Bella/FW
Vista/NN
,/,
Australia/NN
)/)
./.
====================
To/TO
place/VB
the/DT
intraarterial/JJ
catheter/NN
,/,
mice/NNS
were/VBD
anesthetized/VBN
with/IN
avertin/NN
./.
====================
The/DT
standard/JJ
dose/NN
was/VBD
0.014/CD
mL/g/JJ
avertin/NN
,/,
which/WDT
was/VBD
made/VBN
by/IN
diluting/VBG
stock/NN
solution/NN
(/(
for/IN
stock/NN
solution/NN
,/,
10/CD
g/NN
2,2,2/CD
,/,
tribromoethanol/NN
dissolved/JJ
in/IN
10/CD
mL/NNS
tertiary/JJ
amyl/NN
alcohol/NN
)/)
40-fold/JJ
in/IN
0.9/CD
%/NN
NaCl/NN
./.
====================
The/DT
intraarterial/JJ
catheter/NN
,/,
a/DT
polyethylene/NN
tube/NN
(/(
0.2/CD
mm/NN
I.D./NN
,/,
0.5/CD
mm/NN
O.D/NN
./.
)/)
====================
(/(
Natsume/NN
,/,
Tokyo/NNP
,/,
Japan/NNP
)/)
that/WDT
was/VBD
filled/VBN
with/IN
0.9/CD
%/NN
NaCl/NN
containing/VBG
100/CD
U/mL/NN
heparin/NN
,/,
was/VBD
inserted/VBN
into/IN
the/DT
right/JJ
carotid/NN
artery/NN
and/CC
tied/VBN
in/IN
place/NN
./.
====================
The/DT
blood/NN
pressure/NN
in/IN
the/DT
vessel/NN
was/VBD
transmitted/VBN
along/IN
the/DT
catheter/NN
to/TO
the/DT
transducer/NN
's/POS
diaphragm/NN
(/(
MLT0699/NN
Disposable/JJ
BP/NN
Transducer/NN
;/:
ADInstruments/NNS
)/)
./.
====================
The/DT
diaphragm/NN
signal/NN
was/VBD
amplified/VBN
through/IN
a/DT
Bridge/JJ
Amplifier/NN
and/CC
recorded/VBD
on/IN
a/DT
PowerLab/NN
system/NN
(/(
LabChart/NN
7.2/CD
;/:
ADInstruments/NNS
)/)
./.
====================
Blood/NN
pressure/NN
was/VBD
monitored/VBN
for/IN
2/CD
h/NN
after/IN
the/DT
injection/NN
of/IN
the/DT
anesthetic/JJ
and/CC
calculated/VBN
as/IN
the/DT
average/NN
blood/NN
pressure/NN
between/IN
45/CD
min/NN
and/CC
75/CD
min/NN
after/IN
the/DT
injection/NN
(/(
1/CD
point/NN
per/IN
min/NN
)/)
./.
====================
Statistical/JJ
analysis/NN
was/VBD
performed/VBN
using/VBG
PASW/NN
Statistics/NNS
version/NN
18.0/CD
(/(
SPSS/NN
Inc./NNP
,/,
Chicago/NNP
,/,
IL/NN
,/,
USA/NNP
)/)
,/,
and/CC
differences/NNS
in/IN
blood/NN
pressure/NN
between/IN
case/NN
and/CC
control/NN
groups/NNS
were/VBD
analyzed/VBN
by/IN
independent/JJ
sample/NN
t-test/JJS
./.
====================
Reduction/NN
in/IN
Casz1/NN
mRNA/NN
by/IN
siRNA/JJ
injection/NN
into/IN
tail/NN
vein/NN
====================
We/PRP
examined/VBD
the/DT
efficacies/NNS
of/IN
3/CD
Casz1/NN
siRNA/NN
oligonucleotides/NNS
in/IN
the/DT
B16F10/NN
mouse/NN
melanoma/NN
cell/NN
line/NN
./.
====================
By/IN
real-time/VBP
PCR/NN
,/,
Casz1/NN
mRNA/NN
levels/NNS
fell/JJ
0/CD
%/NN
,/,
59/CD
%/NN
,/,
and/CC
54/CD
%/NN
,/,
and/CC
we/PRP
selected/VBD
the/DT
second/JJ
siRNA/NN
for/IN
the/DT
in/FW
vivo/FW
experiments/NNS
./.
====================
Prior/JJ
to/TO
the/DT
injection/NN
of/IN
siRNA/JJ
,/,
Casz1/NN
expression/NN
in/IN
heart/NN
,/,
lung/NN
,/,
liver/NN
,/,
kidney/NN
,/,
spleen/NN
,/,
and/CC
brain/NN
was/VBD
measured/VBN
by/IN
reverse-transcription/NN
PCR/NN
./.
====================
Casz1/NN
was/VBD
expressed/VBN
in/IN
most/JJS
tissues/NNS
and/CC
at/IN
relatively/RB
low/JJ
levels/NNS
in/IN
liver/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Casz1/NN
siRNA/JJ
was/VBD
mixed/VBN
with/IN
polyethylenimine/NN
,/,
and/CC
the/DT
complex/NN
was/VBD
injected/VBN
into/IN
the/DT
tail/NN
veins/NNS
of/IN
mice/NNS
./.
====================
At/IN
24/CD
h/NN
after/IN
siRNA/JJ
injection/NN
,/,
various/JJ
tissues/NNS
of/IN
siRNA-treated/JJ
mice/NNS
were/VBD
analyzed/VBN
with/IN
regard/NN
to/TO
Casz1/NN
mRNA/NN
levels/NNS
./.
====================
Casz1/NN
mRNA/NN
expression/NN
was/VBD
normalized/VBN
to/TO
GAPDH/NN
,/,
and/CC
a/DT
scrambled/VBN
siRNA/NN
was/VBD
used/VBN
as/IN
control/JJ
./.
====================
By/IN
quantitative/JJ
real-time/NN
PCR/NN
,/,
Casz1/NN
mRNA/NN
levels/NNS
declined/VBD
only/RB
in/IN
kidney/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
Casz1/NN
mRNA/NN
levels/NNS
in/IN
the/DT
kidney/NN
fell/NN
by/IN
45/CD
%/NN
,/,
55/CD
%/NN
,/,
and/CC
25/CD
%/NN
after/IN
1/CD
,/,
2/CD
,/,
and/CC
3/CD
injections/NNS
per/IN
day/NN
,/,
respectively/RB
(/(
n/NN
=/JJ
3/CD
for/IN
each/DT
group/NN
)/)
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
Blood/NN
pressure/NN
in/IN
siRNA-injected/JJ
mice/NNS
====================
Blood/NN
pressure/NN
was/VBD
measured/VBN
24/CD
h/NN
after/IN
tail/NN
vein/NN
injection/NN
of/IN
the/DT
scrambled/VBN
or/CC
Casz1/NN
siRNA/JJ
(/(
control/NN
,/,
n/NN
=/JJ
4/CD
;/:
case/NN
,/,
n/NN
=/JJ
3/CD
)/)
./.
====================
Using/VBG
an/DT
intraarterial/JJ
catheter/NN
that/DT
was/VBD
connected/VBN
to/TO
a/DT
pressure/NN
sensor/NN
,/,
we/PRP
recorded/VBD
blood/NN
pressure/NN
continuously/RB
for/IN
2/CD
h/NN
after/IN
anesthesia/NN
./.
====================
Blood/NN
pressure/NN
did/VBD
not/RB
change/VB
after/IN
a/DT
1-time/JJ
injection/NN
(/(
p/NN
=/JJ
0.713/CD
)/)
./.
====================
Thus/RB
,/,
we/PRP
injected/VBD
siRNA/JJ
twice/RB
each/DT
day/NN
(/(
control/NN
,/,
n/NN
=/JJ
4/CD
;/:
case/NN
,/,
n/NN
=/JJ
6/CD
)/)
but/CC
did/VBD
not/RB
observe/VB
any/DT
significant/JJ
difference/NN
between/IN
the/DT
case/NN
and/CC
control/NN
groups/NNS
(/(
p/NN
=/JJ
0.545/CD
)/)
./.
====================
After/IN
3/CD
siRNA/NN
injections/NNS
daily/RB
for/IN
3/CD
days/NNS
,/,
blood/NN
pressure/NN
was/VBD
also/RB
unaffected/JJ
(/(
p/NN
=/JJ
0.297/CD
)/)
(/(
Table/JJ
1/CD
,/,
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
This/DT
study/NN
attempted/VBD
to/TO
validate/VB
CASZ1/NN
as/IN
a/DT
regulator/NN
of/IN
blood/NN
pressure/NN
using/VBG
siRNA/JJ
in/IN
mice/NNS
./.
====================
Although/IN
Casz1/NN
mRNA/NN
levels/NNS
decreased/VBD
by/IN
55/CD
%/NN
in/IN
kidney/NN
,/,
blood/NN
pressure/NN
did/VBD
not/RB
change/VB
on/IN
injection/NN
of/IN
the/DT
siRNA/JJ
complex/NN
into/IN
tail/NN
veins/NNS
./.
====================
It/PRP
is/VBZ
difficult/JJ
to/TO
conclude/VB
that/IN
CASZ1/NN
does/VBZ
not/RB
control/VB
blood/NN
pressure/NN
,/,
because/IN
this/DT
study/NN
has/VBZ
several/JJ
limitations/NNS
./.
====================
First/RB
,/,
Casz1/NN
mRNA/NN
levels/NNS
in/IN
kidney/NN
were/VBD
reduced/VBN
up/IN
to/TO
55/CD
%/NN
;/:
if/IN
Casz1/NN
expression/NN
had/VBD
been/VBN
abolished/VBN
,/,
we/PRP
might/MD
have/VBP
detected/VBN
a/DT
significant/JJ
difference/NN
in/IN
blood/NN
pressure/NN
between/IN
the/DT
case/NN
and/CC
control/NN
groups/NNS
./.
====================
Second/RB
,/,
it/PRP
is/VBZ
possible/JJ
that/IN
CASZ1/NN
functions/NNS
in/IN
other/JJ
tissues/NNS
besides/VBZ
the/DT
kidney/NN
in/IN
the/DT
regulation/NN
of/IN
blood/NN
pressure/NN
./.
====================
The/DT
kidney/NN
is/VBZ
an/DT
essential/JJ
organ/NN
of/IN
the/DT
urinary/JJ
system/NN
and/CC
controls/VBZ
homeostatic/JJ
functions/NNS
,/,
such/JJ
as/IN
the/DT
regulation/NN
of/IN
blood/NN
pressure/NN
,/,
by/IN
maintaining/VBG
salt/NN
and/CC
water/NN
balances/NNS
./.
====================
However/RB
,/,
the/DT
function/NN
of/IN
CASZ1/NN
in/IN
kidney/NN
is/VBZ
unknown/JJ
due/JJ
to/TO
the/DT
lack/NN
of/IN
Casz1/NN
functional/JJ
studies/NNS
in/IN
kidney/NN
./.
====================
Casz1/NN
is/VBZ
highly/RB
expressed/VBN
in/IN
brain/NN
,/,
but/CC
siRNA/JJ
nanoparticles/NNS
do/VBP
not/RB
access/VB
the/DT
brain/NN
due/JJ
to/TO
the/DT
blood-brain/NN
barrier/NN
[/(
15/CD
]/)
./.
====================
Third/RB
,/,
human/JJ
CASZ1/NN
is/VBZ
87/CD
%/NN
and/CC
90/CD
%/NN
identical/JJ
to/TO
mouse/NN
Casz1/NN
in/IN
the/DT
cDNA/NN
and/CC
polypeptide/NN
sequences/NNS
,/,
respectively/RB
[/(
1/CD
]/)
./.
====================
Nevertheless/RB
,/,
it/PRP
is/VBZ
possible/JJ
that/IN
Casz1/NN
function/NN
differs/VBZ
between/IN
the/DT
two/CD
species/NNS
./.
====================
Because/IN
most/JJS
loci/NNS
that/IN
have/VBP
been/VBN
identified/VBN
by/IN
GWASs/NNS
have/VBP
several/JJ
genes/NNS
nearby/JJ
,/,
it/PRP
may/MD
be/VB
necessary/JJ
to/TO
examine/VB
many/JJ
candidates/NNS
to/TO
identify/VB
the/DT
functional/JJ
gene/NN
./.
====================
Knockout/RB
and/CC
transgenic/JJ
mice/NNS
are/VBP
expensive/JJ
and/CC
time-consuming/JJ
to/TO
generate/VB
./.
====================
In/IN
contrast/NN
,/,
siRNA/JJ
injection/NN
costs/NNS
less/RBR
and/CC
is/VBZ
much/RB
faster/JJR
to/TO
perform/VB
,/,
making/VBG
siRNA/NN
injection/NN
suitable/JJ
for/IN
functional/JJ
validation/NN
studies/NNS
of/IN
GWAS/NN
results/NNS
./.
====================
In/IN
summary/NN
,/,
we/PRP
did/VBD
not/RB
observe/VB
any/DT
significant/JJ
change/NN
in/IN
blood/NN
pressure/NN
in/IN
Casz1/NN
siRNA-treated/JJ
mice/NNS
,/,
but/CC
our/PRP$
study/NN
demonstrates/VBZ
the/DT
value/NN
of/IN
in/FW
vivo/FW
siRNA/NN
injection/NN
in/IN
the/DT
functional/JJ
analysis/NN
of/IN
candidate/NN
genes/NNS
from/IN
GWASs/NNS
./.
====================
Casz1/NN
mRNA/NN
expression/NN
in/IN
normal/JJ
mouse/NN
tissues/NNS
./.
====================
GAPDH/NN
,/,
glyceraldehye-3-phosphate/NN
dehydrogenase/NN
./.
====================
Decreases/NNS
in/IN
Casz1/NN
mRNA/NN
by/IN
an/DT
siRNA/JJ
complex/NN
./.
====================
(/(
A/NN
)/)
Fold-change/NN
in/IN
Casz1/NN
mRNA/NN
levels/NNS
in/IN
tissues/NNS
in/IN
siRNA-injected/JJ
mice/NNS
(/(
n/NN
=/JJ
2/CD
per/FW
tissue/NN
)/)
./.
====================
(/(
B/NN
)/)
Reduction/NN
in/IN
Casz1/NN
mRNA/NN
levels/NNS
in/IN
kidney/NN
by/IN
in/FW
vivo/FW
siRNA/NN
injection/NN
./.
====================
Blood/NN
pressure/NN
in/IN
siRNA-injected/JJ
mice/NNS
====================
